Subsequent mRNA and bioinformatics analyses indicated that CBR3-AS1 may have a role in BCR::ABL1-independent TKI resistance in CML patients by targeting KCNA6 [133]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.